“We want to be disciplined financially,” CEO Stéphane Bancel, told Barron’s. Moderna says it has 10 products it hopes to launch over the next few years, including a flu vaccine, a ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna CEO Stephane Bancel has noted, “Messenger RNA is similar to computer technology in several ways that offer promise for lowering costs”. He continues, “We call mRNA the software of life.

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

Moderna (NASDAQ:MRNA) CEO Stéphane Bancel said that the vaccine maker aims to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million in 2026. It expects to end 2025 with ...

In response, Moderna has slashed 2025 guidance twice in the past four months, most recently just eight days after CEO Stephane Bancel wrote in his Moderna 2024 Shareholder Letter that “There are ...

CEO Stéphane Bancel said Moderna has cut its "cash operating cost by over 25 percent compared to 2023" and plans to make further cost cuts of $1 billion in 2025 and $500 million more in 2026 ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

Moderna announced that it hopes to reduce costs ... and reducing costs across our business," CEO Stéphane Bancel said. The stock has dropped more than 65% in the past year.